Five years after initiating our endometriosis alliance with Bayer, we draw some very important lessons from one of our key performance-based alliances – and share our insights. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/excelling-together-for-the-benefit-of-women-suffering-from-endometriosis-5671
Evotec and Bayer advance third endometriosis programme into Phase I clinical development
Evotec AG announced today that its multi-target alliance with Bayer has advanced another promising small molecule into Phase I for the treatment of endometriosis, a painful, debilitating reproductive condition that affects approximately 176 million women worldwide. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-bayer-advance-third-endometriosis-programme-into-phase-i-clinical-development-5669
Evotec forms collaboration with Petra Pharma on INDiGO platform
Evotec AG announced today a strategic collaboration with Petra Pharma Corporation (“Petra”). Through the collaboration, Petra will access Evotec’s INDiGO platform to accelerate the development of its lead programme Petra-01, which is being developed for a range of oncological indications, through to the submission of an Investigational New Drug Application (“IND”) with the U.S. Food and Drug Administration by the close of 2018. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-forms-collaboration-with-petra-pharma-on-indigo-platform-5667
Evotec AG fiscal year 2017 results: Leading external innovation
Evotec AG today reported financial results and corporate updates for the fiscal year ended 31 December 2017. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-fiscal-year-2017-results-leading-external-innovation-5665
Ad hoc: Evotec AG plans conversion into European Company (SE)
Evotec AG today decided to begin preparations for legal conversion of the Company into a European Company (Societas Europaea, SE). The proposal, which has already been approved by the Supervisory Board, will be put to a vote at this year’s Annual General Meeting on 20 June 2018. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hoc-evotec-ag-plans-conversion-into-european-company-se-5663
Evotec launches INDiGO®, a unique integrated drug development solution for accelerating early drug candidates into the clinic
Evotec AG has launched its accelerated drug development service INDiGO®. With the launch of INDiGO®, Evotec’s expertise and capabilities are uniquely combined under one roof to deliver better drug candidates to patients faster and more efficiently than standard industry approaches. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-launches-indigor-a-unique-integrated-drug-development-solution-for-accelerating-early-drug-candidates-into-the-clinic-5660
Evotec AG to report fiscal year 2017 results on 28 March 2018
Evotec AG will report its financial results for 2017 on Wednesday, 28 March 2018. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for fiscal year 2018. The conference call will be held in English. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-to-report-fiscal-year-2017-results-on-28-march-2018-5657
Evotec and Sanofi in exclusive talks to create an Evotec-led infectious disease open innovation R&D platform
Evotec AG and Sanofi have entered into exclusive negotiations for Evotec to accelerate infectious disease research and development through a new open innovation platform near Lyon, France. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-sanofi-in-exclusive-talks-to-create-an-evotec-led-infectious-disease-open-innovation-rd-platform-5646
Ad hoc: Evotec and Sanofi in exclusive talks to create an Evotec-led Infectious Disease open innovation R&D platform
Evotec AG today announced that Evotec and Sanofi have entered into exclusive negotiations to accelerate infectious disease research and development through a new open innovation platform led by Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hoc-evotec-and-sanofi-in-exclusive-talks-to-create-an-evotec-led-infectious-disease-open-innovation-rd-platform-5650
Novo Holdings announce launch of “REPAIR” and formation of Scientific Selection Board
According to a press release published today by Novo Holdings, a new fund has been launched focused on new approaches to fight against antimicrobial resistance. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/novo-holdings-announce-launch-of-repair-and-formation-of-scientific-selection-board-5641